Controlling Symptoms in Patients With MF Treated With Hypomethylating Agents
Srdan Verstovsek, MD, PhD, professor in the Department of Leukemia and director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses how to control symptoms while using hypomethylating agents in patients with myelofibrosis (MF).
The hypomethylating agents are used solely to lower blast and control disease. In some cases, complete responses and partial responses with these agents have been reported, Verstovsek says, but the goal of these agents is to put the disease into a chronic phase with less than 10% blast so that the patient can receive transplant.
According to Verstovsek, the quality of life (QoL) on these agents is not great while MF in general has many systemic symptoms that cannot be controlled by hypomethylating agents. However, to control the symptoms, JAK inhibitor ruxolitinib (Jakafi) can be given in combination to help with QoL and the progressive nature of the disease.
Ruxolitinib, the only approved JAK inhibitor for this setting, is endorsed by the NCCN guidelines for these patients, regardless of their blood cell count, to control symptoms of MF, Verstovsek says.
For more resources and information regarding anticancer targeted therapies in myelofibrosis: http://targetedonc.com/resource-center/MPN
-
Category
No comments found